Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SN30000

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

CEN-209

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids
Multicellular tumour spheroids capture many characteristics of human tumour microenvironments, including hypoxia, and represent… Expand
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
2017
2017
Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice
3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide (SN30- 000), an analog of the well-studied… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
Hypoxia is a prevalent feature of many tumors contributing to disease progression and treatment resistance, and therefore… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • table 2
2014
2014
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
SN30000 is a second-generation benzotriazine-N-oxide hypoxia-activated prodrug scheduled for clinical trial. Previously we showed… Expand
2014
2014
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.
The radical species underlying the activity of the bioreductive anticancer prodrug, SN30000, have been identified by electron… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcome and few validated drug targets. Two… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model
Hypoxia is a significant therapeutic problem for solid tumors because hypoxic cells are treatment-resistant and more aggressive… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Review
2013
Review
2013
Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
Hypoxia contributes to resistance of tumors to some cytotoxic drugs and to radiotherapy, but can in principle be exploited with… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2011
Highly Cited
2011
The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia
Purpose: Benzotriazine-N-oxide bioreductive prodrugs such as tirapazamine and its improved analogue CEN-209 (SN30000) have… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2010
Highly Cited
2010
Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors
Purpose: Tirapazamine (TPZ) has attractive features for targeting hypoxic cells in tumors but has limited clinical activity, in… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE